• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Intelligent Bio Solutions to Participate in Noble Capital Markets' 21st Annual Emerging Growth Equity Conference on December 2-3, 2025

    11/20/25 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care
    Get the next $INBS alert in real time by email

    NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will participate in Noble Capital Markets' 21st Annual Emerging Growth Equity Conference, taking place over December 2-3, 2025, in Boca Raton, Florida.

    Conference Details

    Date:  December 2–3, 2025

    Location:  Florida Atlantic University, Boca Raton, FL

    Presentation Date and Time: Wednesday, December 3, 2025, 11:00 a.m. Eastern Time

    Presentation Location:  Presentation Room 2

    A webcast recording of INBS's presentation will be available the following day on INBS's investor relations website, as well as Noble's website and on Channelchek, for 90 days after the event.

    Interested investors can register to attend here using the discount code INBSNOBLECON.

    For more information about the conference, or to schedule a one-on-one meeting with the INBS management team, please contact your Noble Capital Markets representative or email KCSA Strategic Communications at [email protected].

    About Intelligent Bio Solutions Inc.   

    Intelligent Bio Solutions Inc. (NASDAQ:INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company's current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.   

    For more information, visit https://ibs.inc/ 

    Company Contact  

    Intelligent Bio Solutions Inc.   

    [email protected]    

    LinkedIn | Twitter   

    Investor & Media Contact  

    Valter Pinto, Managing Director   

    KCSA Strategic Communications   

    PH: (212) 896-1254   

    [email protected]  



    Primary Logo

    Get the next $INBS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INBS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $INBS
    SEC Filings

    View All

    Intelligent Bio Solutions Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

    12/12/25 5:05:37 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by Intelligent Bio Solutions Inc.

    S-8 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

    12/5/25 5:00:40 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Intelligent Bio Solutions Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

    12/2/25 8:00:52 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    $INBS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Intelligent Bio Solutions Inc. Announces Reverse Stock Split

    NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("Intelligent Bio Solutions" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it will effect a 1-for-10 reverse split of its common stock, that will become effective at 11:59 pm (Eastern Time) on December 15, 2025. Trading of the Company's common stock on The Nasdaq Capital Market ("Nasdaq") will continue, on a split-adjusted basis, with the opening of the markets on December 16, 2025, under the trading symbol "INBS" and new CUSIP number 36151G709. The reverse stock split was approved by Intelligent Bio Solutions' stock

    12/12/25 10:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Intelligent Bio Solutions to Participate in Noble Capital Markets' 21st Annual Emerging Growth Equity Conference on December 2-3, 2025

    NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will participate in Noble Capital Markets' 21st Annual Emerging Growth Equity Conference, taking place over December 2-3, 2025, in Boca Raton, Florida. Conference DetailsDate:  December 2–3, 2025Location:  Florida Atlantic University, Boca Raton, FL Presentation Date and Time: Wednesday, December 3, 2025, 11:00 a.m. Eastern TimePresentation Location:  Presentation Room 2 A webcast recording of INBS's presentation will be available the followin

    11/20/25 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Intelligent Bio Solutions Reports Fiscal 2026 First Quarter Financial Results and Operational Highlights, Delivering Record Revenue Growth

    Record quarterly revenue of $1.11 million, an increase of 32% sequentially and 28% year-over-year, driven by consumable cartridge sales and customer base expansion Gross profit margins increased 690 basis points year-over-year to 46.6%, reflecting improved operational efficiency and greater revenue percentage from higher margin cartridge sales NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the fiscal first quarter ended September 30, 2025. The fiscal 2026 first

    11/12/25 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    $INBS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Financial Officer Sakiris Spiro Kevin was granted 34,500 shares, increasing direct ownership by 10,952% to 34,815 units (SEC Form 4)

    4/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)

    3/31/25 4:15:27 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Simeonidis Harry was granted 40,000 shares, increasing direct ownership by 9,804% to 40,408 units (SEC Form 4)

    4 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)

    9/27/24 5:00:16 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Sakiris Spiro Kevin was granted 34,500 shares, increasing direct ownership by 10,952% to 34,815 units (SEC Form 4)

    4 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)

    9/27/24 5:00:15 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    $INBS
    Financials

    Live finance-specific insights

    View All

    Intelligent Bio Solutions Reports Fiscal 2026 First Quarter Financial Results and Operational Highlights, Delivering Record Revenue Growth

    Record quarterly revenue of $1.11 million, an increase of 32% sequentially and 28% year-over-year, driven by consumable cartridge sales and customer base expansion Gross profit margins increased 690 basis points year-over-year to 46.6%, reflecting improved operational efficiency and greater revenue percentage from higher margin cartridge sales NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the fiscal first quarter ended September 30, 2025. The fiscal 2026 first

    11/12/25 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Intelligent Bio Solutions Reports Fiscal 2025 Fourth Quarter and Full Year Results, Highlighting Progress on Planned U.S. Market Expansion, Revenue Growth and Increased Operational Efficiencies

    Company advanced efforts to secure U.S. FDA 510(k) clearance to advance on path towards planned U.S. market expansion beyond Forensic Use Only settings Fourth quarter sequential and year-on-year revenue growth of 16%, supported by increased demand for drug testing cartridges NEW YORK, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the fiscal fourth quarter and full-year ended June 30, 2025. Fiscal 2025 marked a year of growth for the Company, driven by higher-margin cart

    8/15/25 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Intelligent Bio Solutions Announces Fiscal Q3 2025 Financial Results and Key Operational Achievements

    20% sequential quarterly revenue growth and 91% year-over-year quarterly gross profit growth Continued momentum from recurring higher-margin cartridge sales now reaching 58% of total sales for the nine months ended March 31, 2025  35 new accounts and international growth during Q3 bring total active accounts to over 450 NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for the fiscal third quarter and nine months ended March 31, 2025, and provided a business update.   The Company delivered a st

    5/13/25 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    $INBS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Intelligent Bio Solutions Inc.

    SC 13G/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

    11/14/24 7:16:17 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Intelligent Bio Solutions Inc.

    SC 13G - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

    11/14/24 4:31:30 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care